PFE Quote, Financials, Valuation and Earnings

Arvinas has a net margin of 2.31% compared to Pfizer's net margin of -76.18%. Pfizer's return on equity of 8.91% beat Arvinas's return on equity of -32.96%.

Pfizer has a consensus price target of $30.16, signalling upside risk potential of 38.15%. On the other hand Arvinas has an analysts' consensus of $36.22 which suggests that it could grow by 373.49%. Given that Arvinas has higher upside potential than Pfizer, analysts believe Arvinas is more attractive than Pfizer.

Pfizer has a beta of 0.670, which suggesting that the stock is 32.954% less volatile than S&P 500. In comparison Arvinas has a beta of 2.305, suggesting its more volatile than the S&P 500 by 130.541%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 7.67%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

Pfizer quarterly revenues are $17.8B, which are larger than Arvinas quarterly revenues of $59.2M. Pfizer's net income of $410M is higher than Arvinas's net income of -$45.1M. Notably, Pfizer's price-to-earnings ratio is 15.63x while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 1.97x versus 2.09x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of 2.31% compared to Pfizer's net margin of 23.56%. Pfizer's return on equity of 8.91% beat Gilead Sciences's return on equity of 2.5%.

Pfizer has a consensus price target of $30.16, signalling upside risk potential of 38.15%. On the other hand Gilead Sciences has an analysts' consensus of $112.50 which suggests that it could grow by 7.27%. Given that Pfizer has higher upside potential than Gilead Sciences, analysts believe Pfizer is more attractive than Gilead Sciences.

Pfizer has a beta of 0.670, which suggesting that the stock is 32.954% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 7.67%. Gilead Sciences offers a yield of 2.96% to investors and pays a quarterly dividend of $0.79 per share. Pfizer pays 118.44% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Pfizer quarterly revenues are $17.8B, which are larger than Gilead Sciences quarterly revenues of $7.6B. Pfizer's net income of $410M is lower than Gilead Sciences's net income of $1.8B. Notably, Pfizer's price-to-earnings ratio is 15.63x while Gilead Sciences's PE ratio is 283.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 1.97x versus 4.59x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 2.31% compared to Pfizer's net margin of 50.24%. Pfizer's return on equity of 8.91% beat Johnson & Johnson's return on equity of 19.98%.

Pfizer has a consensus price target of $30.16, signalling upside risk potential of 38.15%. On the other hand Johnson & Johnson has an analysts' consensus of $170.21 which suggests that it could grow by 10.59%. Given that Pfizer has higher upside potential than Johnson & Johnson, analysts believe Pfizer is more attractive than Johnson & Johnson.

Pfizer has a beta of 0.670, which suggesting that the stock is 32.954% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 7.67%. Johnson & Johnson offers a yield of 3.22% to investors and pays a quarterly dividend of $1.24 per share. Pfizer pays 118.44% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Pfizer quarterly revenues are $17.8B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Pfizer's net income of $410M is lower than Johnson & Johnson's net income of $11B. Notably, Pfizer's price-to-earnings ratio is 15.63x while Johnson & Johnson's PE ratio is 17.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 1.97x versus 4.18x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 2.31% compared to Pfizer's net margin of -117.16%. Pfizer's return on equity of 8.91% beat Moderna's return on equity of -29.09%.

Pfizer has a consensus price target of $30.16, signalling upside risk potential of 38.15%. On the other hand Moderna has an analysts' consensus of $51.14 which suggests that it could grow by 103%. Given that Moderna has higher upside potential than Pfizer, analysts believe Moderna is more attractive than Pfizer.

Pfizer has a beta of 0.670, which suggesting that the stock is 32.954% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 7.67%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Pfizer quarterly revenues are $17.8B, which are larger than Moderna quarterly revenues of $956M. Pfizer's net income of $410M is higher than Moderna's net income of -$1.1B. Notably, Pfizer's price-to-earnings ratio is 15.63x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 1.97x versus 3.06x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.